Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 11,500 shareholders.

For further information, please contact:

Guillaume van Renterghem
LifeSci Advisors, Investor Relations


Updated 2024-04-26